Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеКлиническое исследование I фазыКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marconi Giovanni, Piciocchi Alfonso, Audisio Ernesta, Papayannidis Cristina, Cerrano Marco, Minotti Clara, Paoloni Francesca, Guolo Fabio, Bocchia Monica, Rondoni Michela, Lico Albana, Carrabba Matteo G, Della Porta Matteo Giovanni, Frigeni Marco, Giaccone Luisa, Beltrami Germana, Cattaneo Chiara, Di Chio Maria Chiara, Serio Bianca, Crea Enrico, Freilone Roberto, Capria Saveria, Curti Antonio, Minetto Paola, la Sala Edoardo, Nanni Jacopo, Zannetti Beatrice Anna, Simonetti Giorgia, Bochicchio Maria Teresa, Saglio Giuseppe, Lemoli Roberto M, Venditti Adriano, Vignetti Marco, Fazi Paola, Martinelli Giovanni
Аннотация
The standard induction treatment for acute myeloid leukemia (AML) has limited efficacy for patients with non-low-risk AML. We conducted a multicenter study phase 1b/2, Gruppo Italiano Malattie EMatologiche dell'Adulto AML1718, to investigate the safety and efficacy of venetoclax (VEN) combined with fludarabine, cytarabine, and idarubicin (V-FLAI) as an induction therapy for patients with non-low-risk AML aged <65 years and at intermediate or high European LeukemiaNet risk. After a safety run-in, patients were randomly allocated to VEN 400 mg or VEN 600 mg cohorts. The primary objectives were safety and composite complete remission (bone marrow blasts of <5% with any recovery). We report a predefined interim analysis after 57 patients. Median exposure to VEN during induction was 22 days. Effectiveness and safety were similar between VEN 400 mg and VEN 600 mg cohorts. The 60-day mortality rate was 5.8%. Prolonged aplasia was observed in patients receiving high doses of cytarabine during consolidation. Composite CR was achieved in 84% of patients. With a median follow-up of 20.6 months, 1-year overall survival was 71%, 1-year disease-free survival was 66.2%, and 1-year cumulative incidence of relapse was 24%. V-FLAI is an effective induction therapy for young and fit patients. Fifty-five more patients will be enrolled in part 2; they will receive VEN 400 mg + FLAI as predefined and will be evaluated centrally for measurable residual disease. This trial was registered at www.clinicaltrials.gov as #NCT03455504.